IDENTIFYING SUBCLINICAL TRANSTHYRETIN CARDIAC AMYLOIDOSIS IN ASYMPTOMATIC CARRIERS OF THE V122I TTR ALLELE
IDENTIFYING SUBCLINICAL TRANSTHYRETIN CARDIAC AMYLOIDOSIS IN ASYMPTOMATIC CARRIERS OF THE V122I TTR ALLELE
批准号:
10645211
负责人:
Justin Lee Grodin
金额:
$70.94万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-01 至 2027-06-30
关键词:
AgeAmyloidAmyloidosisBiological MarkersBiophysicsBiopsyBlack PopulationsBlood TestsCardiacCardiologyCarrier StateCessation of lifeClinicDataDiagnosisDiagnostic SpecificityDiseaseDisease ProgressionEarly DiagnosisEarly treatmentEnrollmentEpidemiologyExerciseFamily memberFunctional disorderGadoliniumGenetic ScreeningHeartHeart DiseasesHeart failureImageImaging TechniquesIndividualInfiltrationInheritedIsoleucineKineticsLeft ventricular structureMapsMeasuresMedical GeneticsMethodsMissionModelingMonitorMorbidity - disease rateNational Heart, Lung, and Blood InstituteOnset of illnessPatientsPhenotypePopulationPositioning AttributePrealbuminPreventionPreventive treatmentProcessProteinsPublic HealthRBP4 geneRaceResearchRiskRoleSamplingSerumSeveritiesTestingThickTissuesTreatment FailureUnited StatesUniversitiesValineVariantWorkamyloid imagingamyloidogenesisbiobankbiomarker identificationcardiac amyloidosiscardiac magnetic resonance imagingcarrier statuscarrier testingcirculating biomarkersclinical careclinical research sitecohortcontrast enhanceddiagnostic tooldiagnostic valuedisease diagnosisextracellulargenetic testingimaging detectionimprovedinnovationmortalitymultidisciplinarynovelnovel markernovel therapeuticsphenotypic biomarkerphenotypic dataprematurepreventrecruitscreeningsexspecific biomarkerstreatment strategyvirtual
中文摘要
项目总结
英文摘要
PROJECT SUMMARY
Approximately 1.5 million of the 44 million Blacks in the United States are carriers of the valine-to-isoleucine
substitution at position 122 (V122I) in the transthyretin (TTR) protein. Virtually exclusive to Blacks, this is the
most common cause of hereditary cardiac amyloidosis (hATTR-CA) worldwide. hATTR-CA leads to worsening
heart failure (HF) and premature death. Fortunately, new therapies that stabilize TTR improve morbidity and
mortality in hATTR-CA, especially when prescribed early in the disease.(5) However, hATTR-CA is often
diagnosed at an advanced stage and conventional diagnostic tools lack diagnostic specificity to detect early
disease. Recent work from the author demonstrated that young V122I TTR carriers had indirect imaging and
biomarker evidence of cardiac amyloid infiltration. Thus, the overall objectives of this proposal are to determine
the presence of subclinical hATTR-CA and to identify biomarkers that indicate amyloid progression in V122I TTR
carriers. The central hypothesis of this proposal is that hATTR-CA has a long latency period that will be detected
through subclinical amyloidosis imaging and biomarker phenotyping. The central hypothesis will be tested by
pursuing 2 specific aims: Aim 1) determine the association of V122I TTR carrier status with CMRI evidence of
amyloid infiltration; Sub-aim 1) determine the association of V122I TTR carrier status with cardiac reserve; Aim
2) determine the association between amyloid-specific biomarkers and V122I TTR carrier status; and Sub-aim
2) determine the association of amyloid-specific biomarkers with imaging-based parameters and evaluate their
diagnostic utility for identifying subclinical hATTR-CA. In Aim 1, CMRI will be used to compare metrics associated
with cardiac amyloid infiltration between a cohort of V122I TTR carriers without HF formed by cascade genetic
testing and age-, sex-, and race-matched non-carrier controls. For Sub-Aim 1, a sub-sample of carriers and non-
carrier controls enrolled in Aim 1 will undergo novel exercise CMRI to measure and compare cardiac systolic
and diastolic reserve. Aim 2 involves measuring and comparing amyloid-specific biomarkers in V122I TTR
carriers without HF with samples matched non-carriers (both from Aim 1) and individuals with symptomatic V122I
hATTR-CA from our clinical sites. These biomarkers detect and quantify different processes of TTR
amyloidogenesis and include circulating TTR, retinol binding protein 4, TTR kinetic stability, and misfolded TTR
oligomers. Sub-aim 2 will establish the role of these biomarkers to detect imaging evidence of subclinical hATTR-
CA disease. The research proposed in this application is innovative, in the applicant's opinion, because it will
enroll a large population of V122I TTR carriers without HF through cascade genetic testing that will model clinical
care. Then, it will employ detailed, advanced imaging techniques with tissue characterization and novel
biomarkers that directly quantify processes of hATTR-CA disease progression to identify subclinical hATTR-CA.
Identifying evidence of cardiac amyloid progression prior to hATTR-CA disease onset will change how we think
about this disease and justify future research in screening and treatment strategies to prevent hATTR-CA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
基于聚金属氧酸盐对Amyloid蛋白的定点化学修饰及其在阿尔茨海默症治疗中的应用
-
批准号:22077118
-
项目类别:面上项目
-
资助金额:63.0万元
-
批准年份:2020
-
负责人:高楠
-
依托单位:
基于S1P通路探究Amyloid-β在干性年龄相关性黄斑变性中的作用
-
批准号:81870666
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:王海燕
-
依托单位:
Amyloid-beta-PirB 相互作用介导小胶质细胞表型和功能变化参与AD进展的机制研究
-
批准号:81601123
-
项目类别:青年科学基金项目
-
资助金额:17.0万元
-
批准年份:2016
-
负责人:都瑾
-
依托单位:
Beta-amyloid寡聚体特有的抗原表位多肽疫苗的研究
-
批准号:30971012
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2009
-
负责人:刘瑞田
-
依托单位:
抗阿兹海默病Beta-Amyloid寡聚物单链可变区抗体的筛选及其动物试验
-
批准号:30570622
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2005
-
负责人:刘瑞田
-
依托单位: